CymaBay Therapeutics Inc. (NASDAQ:CBAY) Director Kurt Von Emster sold 50,048 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $9.26, for a total value of $463,444.48. Following the transaction, the director now owns 90,000 shares in the company, valued at $833,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Kurt Von Emster also recently made the following trade(s):
- On Tuesday, October 31st, Kurt Von Emster sold 59,209 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.27, for a total value of $548,867.43.
- On Tuesday, October 3rd, Kurt Von Emster sold 108,876 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $7.85, for a total value of $854,676.60.
- On Friday, September 29th, Kurt Von Emster sold 211,124 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $8.09, for a total value of $1,707,993.16.
CymaBay Therapeutics Inc. (NASDAQ CBAY) traded down $0.85 during trading hours on Tuesday, reaching $8.40. The company had a trading volume of 1,059,700 shares, compared to its average volume of 736,215. CymaBay Therapeutics Inc. has a 1 year low of $1.46 and a 1 year high of $9.40. The company has a current ratio of 7.39, a quick ratio of 7.39 and a debt-to-equity ratio of 0.04.
CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). During the same period in the previous year, the business earned ($0.25) earnings per share. sell-side analysts anticipate that CymaBay Therapeutics Inc. will post -0.83 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its position in shares of CymaBay Therapeutics by 0.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 140 shares during the period. Marshall Wace North America L.P. acquired a new position in shares of CymaBay Therapeutics in the 2nd quarter valued at $242,000. Ardsley Advisory Partners boosted its position in shares of CymaBay Therapeutics by 66.2% in the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock valued at $290,000 after purchasing an additional 20,000 shares during the period. Boothbay Fund Management LLC acquired a new position in shares of CymaBay Therapeutics in the 3rd quarter valued at $404,000. Finally, Renaissance Technologies LLC boosted its position in CymaBay Therapeutics by 97.6% during the 1st quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock worth $997,000 after acquiring an additional 114,549 shares during the period. Institutional investors and hedge funds own 27.08% of the company’s stock.
CBAY has been the topic of several research analyst reports. Piper Jaffray Companies set a $7.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 17th. HC Wainwright increased their target price on CymaBay Therapeutics from $7.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, July 17th. BidaskClub lowered CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 3rd. SunTrust Banks, Inc. initiated coverage on CymaBay Therapeutics in a research report on Friday, August 18th. They issued a “buy” rating and a $15.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $16.00 target price on shares of CymaBay Therapeutics in a research report on Tuesday, September 26th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $14.00.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.